
TuHURA Biosciences, Inc. (NASDAQ:HURA – Free Report) – Analysts at Brookline Capital Markets lifted their FY2026 earnings per share (EPS) estimates for TuHURA Biosciences in a note issued to investors on Monday, November 16th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.46) per share for the year, up from their previous estimate of ($0.58). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.57) per share. Brookline Capital Markets also issued estimates for TuHURA Biosciences’ Q4 2026 earnings at ($0.10) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.48 EPS.
Several other research firms also recently issued reports on HURA. Citizens Jmp restated a “market outperform” rating and set a $9.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, August 18th. HC Wainwright reiterated a “buy” rating on shares of TuHURA Biosciences in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.50.
TuHURA Biosciences Stock Performance
NASDAQ HURA opened at $1.37 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 0.47 and a quick ratio of 0.18. The firm has a market capitalization of $90.09 million, a price-to-earnings ratio of -2.74 and a beta of -0.23. The company’s fifty day moving average is $1.88 and its two-hundred day moving average is $2.01. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in TuHURA Biosciences during the second quarter valued at approximately $1,615,000. Fifth Third Bancorp bought a new position in shares of TuHURA Biosciences during the 3rd quarter worth approximately $1,095,000. Cetera Investment Advisers bought a new position in shares of TuHURA Biosciences during the 1st quarter worth approximately $251,000. Bank of New York Mellon Corp acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $285,000. Finally, WealthShield Partners LLC acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $214,000. Institutional investors own 0.62% of the company’s stock.
Key TuHURA Biosciences News
Investors following HURA have been watching these news items:
- Positive Sentiment: HC Wainwright raised its 2026 and 2027 EPS forecasts, including improving its FY2027 estimate to a loss of $0.39 per share from $0.61, and reaffirmed its Buy rating. Brookline also lifted several forecasts, including FY2029 to $0.05 per share and FY2030 to $0.48. Less-negative estimates and a projected longer-term move to profitability may support investor sentiment. TuHURA analyst estimates
- Neutral Sentiment: The reports concern analyst forecasts rather than new company results or a clinical, regulatory, or commercial development, so they do not confirm that earnings will improve as projected. HC Wainwright Buy rating
- Negative Sentiment: Despite the favorable revisions, the supplied market data places HURA below its 50-day and 200-day moving averages, indicating ongoing share-price weakness that could temper the positive analyst news.
About TuHURA Biosciences
TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.
Read More
- Five stocks we like better than TuHURA Biosciences
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
